Rodrigo Caceres-Robles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rodrigo Caceres-Robles has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Yessenia Yauri-Huaman
Laboratorio de Investigación en Neurociencias, Instituto Científico, Facultad de Ciencias de la Salud, Universidad Andina del Cusco, Cusco 08006, Peru
3 shared publications - Agustín Jara
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Alberto Lazarowski
Instituto de Neurociencias de Castilla y León (INCYL), Universidad de Salamanca, 37007 Salamanca, Spain
2 shared publications - Claudia Taborda Gómez
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Florencia Fernandez
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Franco Moscovicz
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 851
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.
- 11 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 851
Open AccessSubchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.
- Open Access
- 29 June 2026
- Published by MDPI AG in Preprints.org
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus
In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms For this reason, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury and one of its main characteristics is an increased susceptibility to seizures due to reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. We developed an experimental protocol to discretely measure seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/ every 10 minutes). Using the DMST, we observed a significant decrease in seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20mg/kg) for 14 days following SE. Treatment with CBD did not improve seizure threshold, moreover, it worsened the hypersensitivity state, and delayed the recovery following SE. Our results suggest that orally administered CBD, at a human therapeutically recommended and safe dose, does not improve susceptibility to seizure development after SE.
- 29 June 2026
- Published by MDPI AG in Preprints.org
Open AccessSubchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus
In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms For this reason, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury and one of its main characteristics is an increased susceptibility to seizures due to reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. We developed an experimental protocol to discretely measure seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/ every 10 minutes). Using the DMST, we observed a significant decrease in seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20mg/kg) for 14 days following SE. Treatment with CBD did not improve seizure threshold, moreover, it worsened the hypersensitivity state, and delayed the recovery following SE. Our results suggest that orally administered CBD, at a human therapeutically recommended and safe dose, does not improve susceptibility to seizure development after SE.
- Open Access
- 27 June 2025
- Published by Universidad Nacional de San Antonio Abad del Cusco in Q'EUÑA
- Vol. 16 (1) , 13-25
Efectos de Crisis Convulsivas Inducidas por Kindling con Pentilentetrazol a Largo Plazo sobre Neuroinflamación: Análisis Inmunohistoquímico y EEG en Ratas
El presente estudio experimental describe los efectos del kindling inducido por PTZ, un modelo animal validado y ampliamente utilizado para estudiar la epileptogénesis mediante la inducción progresiva de convulsiones. La investigación se centra en el análisis descriptivo de la fase post-kindling, tanto a nivel de la actividad cerebral como molecular. Para este fin 12 ratas fueron sometidas a un protocolo de tres etapas: habituación, challenge (60 mg/kg) y kindling que consta de la administración repetida de PTZ a dosis sub- convulsivantes (35 mg/kg), y el grupo control conformado por 6 ratas, que solo fue expuesto a inyecciones de solución salina. En el primer mes de la fase post-kindling se implantaron electrodos epidurales a un subconjunto de los sujetos para evaluar los registros de electroencefalograma (EEG). Al segundo mes de la fase post-kindling otros sujetos fueron destinados para el análisis molecular mediante la técnica de inmunohistoquímica (IHQ) e inmunofluorescencia (IF) con los anticuerpos GFAP y NeuN como marcadores de astrocitos y neuronas maduras respectivamente. Estos análisis se repitieron en el tercer mes posterior al kindling. Los resultados obtenidos mediante EEG evidenciaron eventos interictales en ratas durante el primer mes de la fase post-kindling. Al segundo y tercer mes, se observó un incremento notable del marcador GFAP para astrocitos, sin cambios notables en la expresión de NeuN para estructuras del hipocampo (CA1, CA3 y Giro Dentado). Estos resultados contribuyen a la caracterización de la fase post-kindling, favoreciendo una mejor comprensión de los mecanismos subyacentes del modelo PTZ y de su evolución temporal.
- 27 June 2025
- Published by Universidad Nacional de San Antonio Abad del Cusco in Q'EUÑA
- Vol. 16 (1) , 13-25
Open AccessEfectos de Crisis Convulsivas Inducidas por Kindling con Pentilentetrazol a Largo Plazo sobre Neuroinflamación: Análisis Inmunohistoquímico y EEG en Ratas
El presente estudio experimental describe los efectos del kindling inducido por PTZ, un modelo animal validado y ampliamente utilizado para estudiar la epileptogénesis mediante la inducción progresiva de convulsiones. La investigación se centra en el análisis descriptivo de la fase post-kindling, tanto a nivel de la actividad cerebral como molecular. Para este fin 12 ratas fueron sometidas a un protocolo de tres etapas: habituación, challenge (60 mg/kg) y kindling que consta de la administración repetida de PTZ a dosis sub- convulsivantes (35 mg/kg), y el grupo control conformado por 6 ratas, que solo fue expuesto a inyecciones de solución salina. En el primer mes de la fase post-kindling se implantaron electrodos epidurales a un subconjunto de los sujetos para evaluar los registros de electroencefalograma (EEG). Al segundo mes de la fase post-kindling otros sujetos fueron destinados para el análisis molecular mediante la técnica de inmunohistoquímica (IHQ) e inmunofluorescencia (IF) con los anticuerpos GFAP y NeuN como marcadores de astrocitos y neuronas maduras respectivamente. Estos análisis se repitieron en el tercer mes posterior al kindling. Los resultados obtenidos mediante EEG evidenciaron eventos interictales en ratas durante el primer mes de la fase post-kindling. Al segundo y tercer mes, se observó un incremento notable del marcador GFAP para astrocitos, sin cambios notables en la expresión de NeuN para estructuras del hipocampo (CA1, CA3 y Giro Dentado). Estos resultados contribuyen a la caracterización de la fase post-kindling, favoreciendo una mejor comprensión de los mecanismos subyacentes del modelo PTZ y de su evolución temporal.